Bibliography

Bibliography

  1. O’Hara J, Ho W, Linden D, Mawe G, Sharkey K. Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. Am J Physiol Gastrointest Liver Physiol. 2004;287(5): G998–G1007.
  2. Pazos-Moura C, Ortiga-Carvalho T, Gaspar de Moura E. The autocrine/paracrine regulation of thyrotropin secretion. Thyroid. 2004;13:2.
  3. Bogaard H, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135:794–804.
  4. Carey R. Renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension. 2001;38:297–302.
  5. Li, Y. et al. Prospective Study of Restless Legs Syndrome and Risk of Depression in Women Am J Epidemiol. 2012;176(4):279–288
  6. Clausius, N. et al. The relevance of dopamine agonists in the treatment of depression, Neuropsychiatry. 2009;23(1):15-25.
  7. Wolfe, N. et al. Neuropsychological profile linked to low dopamine: in Alzheimer’s disease, major depression, and Parkinson’s disease” Journal of Neurology, Neurosurgery, and Psychiatry 1990;53:915-917
  8. Homan, P. et al. Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression. Translational Psychiatry volume 5, pagee532(2015)
  9. Cho, H. et al. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology Current Opinion in Psychiatry 2006, 19:67–73
  10. Steegmans, P. et al. Low serum cholesterol concentration and serotonin metabolism in men BMJ Vol 312 27 January 1996
  11. Sobczak, S. et al. Effects of Acute Tryptophan Depletion on Mood and Cortisol Release in First degree
    Relatives of Type I and Type II Bipolar Patients and Healthy Matched Controls Neuropsychopharmacology 27:834–842, 2002
  12. Giurgiuca, A. et al. Suicide risk is associated with low levels of platelet serotonin in bipolar I disorder Rom J Leg Med [25] 205-210
  13. Crockett, M. et al. Serotonin and aversive processing in affective and social decision-making Current Opinion in Behavioral Sciences 2015, 5:64–70
  14. Muck-Seler, D. et al. Serotonin, Periodicum Biologorum VOL. 113, No 1, 29–41, 2011
  15. Trachte G, et al. Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population. Neuropsychiatry Dis Treat. 2009;5:227 235.
  16. Koepsell H. Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol. 1998;60:243–266.
  17. Udenfriend S, Titus E, Weissbach H, Peterson RE. Biogenesis and metabolism of 5-hydroxyindole compounds. J Biol Chem. 1956;219:335–344.
  18. Davidson J, Sjoerdsma A, Loomis LN, Udenfriend S. Studies with the serotonin precursor, 5-hydroxytryptophan, in experimental animals and man. J Clin Invest. 1957;36:1594–1599.
  19. Graefe K-H, Friedgen B, Wolfel R, Bossle F, Russ H, Schomig E. 1,1’-Diisopropyl-2,4’-cyanine (disprocynium24), a potent uptake2 blocker, inhibits the renal excretion of catecholamines. Naunyn Schmiedebergs Arch Pharmacol. 1997;356:115–125.
  20. Wa TCLK, Burns NJT, Williams BC, Freestone S, Lee MR. Blood and urine 5-hydroxytryptophan and 5-hydroxytryptamine levels after administration of two 5-hydroxytryptamine precursors in normal man. Br J Clin Pharmacol. 1995;39:327–329.
  21. Stier CT, Brewer TF, Dick LB, Wynn N, Itskovitz HD. Formation of biogenic amines by isolated kidneys of spontaneously hypertensive rats. Life Sci. 1986;38:7–14.
  22. Wang Z-Q, Siragy HM, Felder RA, Carey RM. Intrarenal dopamine production and distribution in the rat. Hypertension. 1997;29(1 Pt 2): 228–234.
  23. Berndt TJ, Liang M, Tyce GM, Knox FG. Intrarenal serotonin, dopamine and phosphate handling in remnant kidneys. Kidney Int. 2001;59:625–630.
  24. Chan YL. Cellular mechanisms of renal tubular transport of L-DOPA its derivative in the rat: microperfusion studies. J Pharmacol Exp Ther. 1976;199:17–24.
  25. Gründemann D, Köster S, Kiefer N, et al. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem. 1998;273:30915–30920.
  26. Baines AD, Craan A, Morgunov N. Tubular secretion and metabolism of dopamine, norepinephrine, methoxtyramine and normetanephrine by the rat kidney. J Pharmacol Exp Ther. 1979;208:144–147.
  27. Wa TCLK, Freestone S, Samson RR, Johnston NR, Lee MR. A comparison of the effects of two putative 5 hydroxytryptamine renal prodrugs in normal man. Br J Clin Pharmacol. 1993;36:19-23.
  28. Agharanya JC, Alonso R, Wurtman RJ. Changes in catecholamine excretion after short-term tyrosine ingestion in normally fed human subjects. Am J Clin Nutr. 1981;34:82–87.
  29. FDA medical food criteria; https://www.fda.gov/media/97726/download
  30. R&R Product Information; https://hinzmedicalfoods.com/wpcontent/
    uploads/2021/01/RnRProductInfoOct2020.pdf
  31. Lodosyn prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017830s014s016s017s018s019s0 30lbl.pdf
  32. Rojo-Sebastián, A. et al. Vitamin B6 Deficiency in Patients With Parkinson Disease Treated With Levodopa/Carbidopa clinical Neuropharmacology Vol 43, Number 5, Sep/Oct 2020FDA
  33. DDC Gene, Medline Plus https://medlineplus.gov/genetics/gene/ddc/
  34. Paradoxical reaction Wikipedia https://en.wikipedia.org/wiki/Paradoxical_reaction
  35. Gandhi, K. et al. Levodopa (L-Dopa) StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan
  36. Demasio, Antonio et al. Psychiatric aspects in Parkinsonism treated with L-dopa J. Neurol. Neurosurg. Psychiatry., 1971, 34, 502-507
  37. Jaunarajs, K. et al. Potential mechanisms underlying anxiety and depression in Parkinson’s disease: consequences of L-DOPA treatment 2011 January ; 35(3): 556–564.
  38. Nausieda, P. et al. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis Clin Neuropharmacol 1982;5(2):183-94
  39. Patil, S. et al. Biological sources of L-DOPA: An alternative approach, Advances in Parkinson’s disease Vol.2, No.3, 81-87 (2013)
  40. Przuntek, H. et al. Bromocriptine lessens the incidence of mortality in L-Dopa-treated
  41. parkinsonian patients: prado-study discontinued, Eur J Clin Pharmacol (1992) 43:357-363
  42. DBS Labs database, Tom Uncini, MD medical director Duluth, MN